BioCentury | Mar 8, 2010
Clinical News

SUBA-Itraconazole: Pivotal trial data

...of SUBA-Itraconazole was bioequivalent to Sporanox itraconazole from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). Halcygen...
...Halcygen previously had exclusive, worldwide rights to the compound outside of Australia and New Zealand. HalcyGen Pharmaceuticals Ltd....
BioCentury | Oct 5, 2009
Company News

HalcyGen, Hospira deal

...The deal gives HalcyGen full control over SUBA-Itraconazole, which it licensed from Mayne in 2007. HalcyGen...
...an MAA for the oral capsule formulation of itraconazole to treat fungal infections in 2010. HalcyGen...
...its specialty injectable and medication management systems. The deal is expected to close this month. HalcyGen Pharmaceuticals Ltd....
BioCentury | Oct 5, 2009
Financial News

HalcyGen completes debt financing

HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Business: Infectious Date completed: 9/25/09 Type: Debt financing Raised: $10 million Investors: National Australia Bank Note: The debt is a two-year loan. WIR Staff...
BioCentury | Oct 5, 2009
Financial News

HalcyGen completes private placement

HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Business: Infectious Date completed: 9/25/09 Type: Private placement Raised: A$2.3 million (US$2 million) Shares: 11.4 million Price: A$0.20 Shares after offering: 87.5 million Underwriter: Patersons Securities Investors: Institutional investors...
BioCentury | Oct 13, 2008
Clinical News

Subazole: Pivotal trial data

...Halcygen has exclusive worldwide rights to SUBA-Itraconazole outside of Australia and New Zealand from Hospira. HalcyGen Pharmaceuticals Ltd....
BioCentury | Jun 23, 2008
Clinical News

Subazole: Pivotal trial started

...Halcygen has exclusive worldwide rights outside of Australia and New Zealand for SUBA-Itraconazole from Hospira. HalcyGen Pharmaceuticals Ltd....
BioCentury | Jun 16, 2008
Clinical News

HalcyGen, Hospira preclinical data

...HalcyGen has exclusive worldwide rights outside of Australia and New Zealand to Subazole from Hospira. HalcyGen Pharmaceuticals Ltd....
BioCentury | Dec 3, 2007
Clinical News

Subazole: Phase III start

...HGN has exclusive worldwide rights outside of Australia and New Zealand for Subazole from HSP. HalcyGen Pharmaceuticals Ltd....
BioCentury | Aug 13, 2007
Clinical News

SUBA-Itraconazole: Phase II started

...New Zealand from Mayne Pharma Pty Ltd., which was acquired by HSP earlier this year. HalcyGen Pharmaceuticals Ltd....
BioCentury | Jul 9, 2007
Clinical News

SUBA-Itraconazole: Phase II data

...HGN has an exclusive worldwide license excluding Australia and New Zealand for SUBA-Itraconazole from HSP. HalcyGen Pharmaceuticals Ltd....
Items per page:
1 - 10 of 13
BioCentury | Mar 8, 2010
Clinical News

SUBA-Itraconazole: Pivotal trial data

...of SUBA-Itraconazole was bioequivalent to Sporanox itraconazole from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). Halcygen...
...Halcygen previously had exclusive, worldwide rights to the compound outside of Australia and New Zealand. HalcyGen Pharmaceuticals Ltd....
BioCentury | Oct 5, 2009
Company News

HalcyGen, Hospira deal

...The deal gives HalcyGen full control over SUBA-Itraconazole, which it licensed from Mayne in 2007. HalcyGen...
...an MAA for the oral capsule formulation of itraconazole to treat fungal infections in 2010. HalcyGen...
...its specialty injectable and medication management systems. The deal is expected to close this month. HalcyGen Pharmaceuticals Ltd....
BioCentury | Oct 5, 2009
Financial News

HalcyGen completes debt financing

HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Business: Infectious Date completed: 9/25/09 Type: Debt financing Raised: $10 million Investors: National Australia Bank Note: The debt is a two-year loan. WIR Staff...
BioCentury | Oct 5, 2009
Financial News

HalcyGen completes private placement

HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Business: Infectious Date completed: 9/25/09 Type: Private placement Raised: A$2.3 million (US$2 million) Shares: 11.4 million Price: A$0.20 Shares after offering: 87.5 million Underwriter: Patersons Securities Investors: Institutional investors...
BioCentury | Oct 13, 2008
Clinical News

Subazole: Pivotal trial data

...Halcygen has exclusive worldwide rights to SUBA-Itraconazole outside of Australia and New Zealand from Hospira. HalcyGen Pharmaceuticals Ltd....
BioCentury | Jun 23, 2008
Clinical News

Subazole: Pivotal trial started

...Halcygen has exclusive worldwide rights outside of Australia and New Zealand for SUBA-Itraconazole from Hospira. HalcyGen Pharmaceuticals Ltd....
BioCentury | Jun 16, 2008
Clinical News

HalcyGen, Hospira preclinical data

...HalcyGen has exclusive worldwide rights outside of Australia and New Zealand to Subazole from Hospira. HalcyGen Pharmaceuticals Ltd....
BioCentury | Dec 3, 2007
Clinical News

Subazole: Phase III start

...HGN has exclusive worldwide rights outside of Australia and New Zealand for Subazole from HSP. HalcyGen Pharmaceuticals Ltd....
BioCentury | Aug 13, 2007
Clinical News

SUBA-Itraconazole: Phase II started

...New Zealand from Mayne Pharma Pty Ltd., which was acquired by HSP earlier this year. HalcyGen Pharmaceuticals Ltd....
BioCentury | Jul 9, 2007
Clinical News

SUBA-Itraconazole: Phase II data

...HGN has an exclusive worldwide license excluding Australia and New Zealand for SUBA-Itraconazole from HSP. HalcyGen Pharmaceuticals Ltd....
Items per page:
1 - 10 of 13